Xbrane Biopharma ABs interim report for the period January – March 2017 is now available on the Company’s website, www.xbrane.com
Period January – March
- Net sales SEK 6,840 thousand (854)
- Total income SEK 6,980 thousand (861)
- Earnings before tax SEK -10,134 thousand (-5,530)
- Cash flow from current operations SEK -9,353 thousand (-7,556)
- Earnings per share before dilution SEK -2.19 (-2.48)
Significant events during the period
- Xbrane received GMP certificate for the Spherotide production facility in Italy from AIFA (Italian Medicines Agency).
- Xbrane delivered its first batch of Spherotide to a value of SEK 7 million to its partner in the Middle East.
- Xbrane reported positive comparative pre-clinical data on Xlucane.
Significant events after the period
- Xbrane reported positive comparative in vivo effect data on Spherotide.
- Xbrane recruits Susanna Helgesen as new CFO / Head of Investor Relations.
For further information, please contact:
Martin Åmark
Chief Executive Officer
Tel: +46 (0) 763-093 777
E-mail: martin.amark@xbrane.com
Susanna Helgesen
CFO/IR
Tel: +46 (0) 708-278 636
E-mail: susanna.helgesen@xbrane.com
